Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?
PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.
Medical Devices & Diagnostics
Pharma & Biotech
Why Bayer’s HYRNUO first-line FDA review could reshape HER2-mutated NSCLC treatment sequencing
Bayer has FDA momentum in HER2-mutated lung cancer. The harder test is whether HYRNUO can move earlier without stronger survival data.
Medical Devices & Diagnostics
What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Medical Devices & Diagnostics
Valar Labs FDA breakthrough nod signals new test for AI-led bladder cancer risk prediction
Bladder cancer risk tools leave gray zones. Valar Labs’ FDA breakthrough nod tests whether AI pathology can narrow them.
Pharma & Biotech
FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.
Pharma & Biotech
Why Partner Therapeutics’ BIZENGRI approval matters beyond cholangiocarcinoma
Rare cancer biology is becoming commercially actionable. BIZENGRI’s FDA approval puts NRG1 fusion testing under sharper scrutiny.
Medical Devices & Diagnostics
Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
Medical Devices & Diagnostics
What Roche’s $1.05bn PathAI move reveals about the future of pathology labs
Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.
Medical Devices & Diagnostics
Can Caris Life Sciences turn Caris Assure into a broader precision oncology platform?
Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.
Medical Devices & Diagnostics
How Agendia’s breast cancer assays are testing the limits of race-based clinical assumptions
Race matters in care access, but tumor biology may drive response. Agendia’s FLEX data sharpen the breast cancer equity debate.